European Regulatory Round-Up: Research Partners And Parallel Traders
EU’s Innovative Medicines Initiative Builds On Closer U.S. Ties
You may also be interested in...
The latest public-private partnerships to be announced under the EU’s Innovative Medicines Initiative includes the StemBANCC project involving 10 pharmaceutical companies and 23 academic institutions working together to develop patient-derived induced stem cell lines for drug development.
Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.
Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.